157 related articles for article (PubMed ID: 38064927)
41. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
42. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development.
Lu C; Di L
Biopharm Drug Dispos; 2020 Feb; 41(1-2):3-31. PubMed ID: 31778578
[TBL] [Abstract][Full Text] [Related]
44. Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model.
Varma MV; Bi YA; Kimoto E; Lin J
J Pharmacol Exp Ther; 2014 Oct; 351(1):214-23. PubMed ID: 25107633
[TBL] [Abstract][Full Text] [Related]
45. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
Feng B; Varma MV; Costales C; Zhang H; Tremaine L
Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
[TBL] [Abstract][Full Text] [Related]
46. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.
Zamek-Gliszczynski MJ; Lee CA; Poirier A; Bentz J; Chu X; Ellens H; Ishikawa T; Jamei M; Kalvass JC; Nagar S; Pang KS; Korzekwa K; Swaan PW; Taub ME; Zhao P; Galetin A;
Clin Pharmacol Ther; 2013 Jul; 94(1):64-79. PubMed ID: 23588311
[TBL] [Abstract][Full Text] [Related]
47. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
[TBL] [Abstract][Full Text] [Related]
48. In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters.
Gopaul VS; Vildhede A; Andersson TB; Erlandsson F; Lee CA; Johansson S; Hilgendorf C
J Pharmacol Exp Ther; 2021 Aug; 378(2):108-123. PubMed ID: 34074714
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
[TBL] [Abstract][Full Text] [Related]
50. In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018.
Yu J; Ragueneau-Majlessi I
Clin Transl Sci; 2020 Jul; 13(4):693-699. PubMed ID: 31981398
[TBL] [Abstract][Full Text] [Related]
51. In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods.
Yoshida K; Zhao P; Zhang L; Abernethy DR; Rekić D; Reynolds KS; Galetin A; Huang SM
J Pharm Sci; 2017 Sep; 106(9):2209-2213. PubMed ID: 28456729
[TBL] [Abstract][Full Text] [Related]
52. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
53. Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes.
Yang Y; Li P; Zhang Z; Wang Z; Liu L; Liu X
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987693
[TBL] [Abstract][Full Text] [Related]
54. Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity.
Alim K; Bruyère A; Lescoat A; Jouan E; Lecureur V; Le Vée M; Fardel O
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):259-271. PubMed ID: 33292029
[No Abstract] [Full Text] [Related]
55. Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution.
Kirby BJ; Unadkat JD
Drug Metab Dispos; 2010 Nov; 38(11):1926-33. PubMed ID: 20724498
[TBL] [Abstract][Full Text] [Related]
56. Risk of Enzyme- and Transporter-Mediated Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2022: A Detailed Analysis of In Vitro and Clinical Data Available in New Drug Application Reviews.
Yu J; Wang Y; Ragueneau-Majlessi I
Clin Ther; 2024 May; ():. PubMed ID: 38734524
[TBL] [Abstract][Full Text] [Related]
57. Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation.
Tornio A; Filppula AM; Niemi M; Backman JT
Clin Pharmacol Ther; 2019 Jun; 105(6):1345-1361. PubMed ID: 30916389
[TBL] [Abstract][Full Text] [Related]
58. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Varma MV; Lai Y; Feng B; Litchfield J; Goosen TC; Bergman A
Pharm Res; 2012 Oct; 29(10):2860-73. PubMed ID: 22638872
[TBL] [Abstract][Full Text] [Related]
59. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
Ohno Y; Hisaka A; Ueno M; Suzuki H
Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
[TBL] [Abstract][Full Text] [Related]
60. Drug-drug interactions related to altered absorption and plasma protein binding: theoretical and regulatory considerations, and an industry perspective.
Hochman J; Tang C; Prueksaritanont T
J Pharm Sci; 2015 Mar; 104(3):916-29. PubMed ID: 25557998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
